OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

August 16th 2022

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Dr Tarantino on Second-line Treatment Selection in HER2+ Metastatic Breast Cancer

August 16th 2022

Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.

Dr. Melosky on the Use of Lurbinectedin in SCLC

August 16th 2022

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Dr. Beckermann on the Future of Treatment in RCC

August 16th 2022

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Dr. Ryan on Objectives for Investigating Ibrutinib Plus Obinutuzumab in R/R CLL

August 16th 2022

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Shah on How to Address CAR T-Cell Therapy Failure in Hematologic Malignancies

August 16th 2022

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Dr. He on the Future of Durvalumab Plus Chemotherapy in Biliary Tract Cancer

August 12th 2022

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic Cancer

August 11th 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC

August 11th 2022

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL

August 11th 2022

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

August 11th 2022

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Dr. Danilov on the Future of BTK Inhibitors in CLL

August 10th 2022

Alexey V. Danilov, MD, PhD, discusses the future of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Beckermann on the Need for Biomarkers in Frontline RCC

August 10th 2022

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Dr. Hamilton on Tests to Identify HER2-Low and HER2+ Breast Cancer

August 10th 2022

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

August 9th 2022

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

August 8th 2022

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Dr. Marmarelis on the Efficacy of Lazertinib/Amivantamab Plus Chemotherapy in EGFR-Mutated NSCLC

August 8th 2022

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer

August 8th 2022

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.